Metformin treatment

PreclinicalSmall molecule

KKristian Karstoft

Metformin treatment is one of 94 small molecule programs targeting Autism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AutismActive, not recruiting

PrediabetesCompleted

InteractionCompleted

AutismPreclinical

Active, not recruiting

PrediabetesPreclinical

Completed

InteractionPreclinical

Completed

Competition

Competitive Landscape

62 competitors in Interaction

#DrugCompanyPhaseTrials

Versed

CConrado Roberto Hoffmann Filho

Approved

91 2

Estrace

Novo Nordisk

Approved

2 3

Robitussin

Pfizer

Phase 3

10 4

Rifadin

Sanofi

Phase 2

34 5

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

77 6

Rifampicin

Boehringer Ingelheim

Phase 3

22 7

Crestor

AstraZeneca

Phase 1

61 8

Tegretol

Novartis

Phase 1

16 9

Lanoxin

Oxycontin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Autism

NCT06762041

Clinical

Trials by Indication[1]

Interaction2 trials

The Interaction Between Metformin and Acute Exercise

Completed·KKristian Karstoft·N/A·NCT03329651·34 enrolled

The Interaction Between Metformin and Physical Training

Completed·KKristian Karstoft·N/A·NCT03316690·34 enrolled

Autism1 trial

Effects of Metformin on Androgens and Other Steroid Hormones in Affected Subjects With Autism

Not yet recruiting·IInsel Gruppe AG, University Hospital Bern··NCT06762041·20 enrolled

PreDiabetes1 trial

Metformin and Molecular Aging in Prediabetes

Completed·DDiabetes Foundation, India·N/A·NCT07302932·112 enrolled

Arthritis, Rheumatoid1 trial

Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients

Completed·UUniversity Hospital, Bordeaux·Phase 2·NCT04196868·128 enrolled

Schizophrenia1 trial

The Effect of Metformin Treatment on Cognitive Impairment in Individuals With Schizophrenia: A 24-week Multicentre Randomised Controlled Trial

Completed·CCentral South University·Phase 3·NCT05838573·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Metformin treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metformin treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metformin treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kristian Karstoft company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKristian Karstoft

Metformin treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Interaction2 trials

Autism1 trial

PreDiabetes1 trial

Arthritis, Rheumatoid1 trial

Schizophrenia1 trial

References

Drug Info

Quick Facts

Related News